Last reviewed · How we verify
Cytogam
At a glance
| Generic name | Cytogam |
|---|---|
| Also known as | Cytomegalovirus Immune Globulin Intravenous, CMV-IGIV |
| Sponsor | Fernanda P Silveira, MD, MS |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV) (PHASE4)
- CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients (PHASE1, PHASE2)
- Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation. (PHASE2)
- CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients (PHASE4)
- Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion) (PHASE3)
- Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV Infection (PHASE2)
- A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV) (PHASE3)
- Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cytogam CI brief — competitive landscape report
- Cytogam updates RSS · CI watch RSS
- Fernanda P Silveira, MD, MS portfolio CI